2012
Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA. Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. Clinical Infectious Diseases 2012, 54: 1364-1372. PMID: 22460971, PMCID: PMC3404691, DOI: 10.1093/cid/cis203.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAnti-HIV AgentsCD4 Lymphocyte CountCohort StudiesDeveloped CountriesDrug Therapy, CombinationEuropeFemaleHIV InfectionsHIV SeropositivityHumansImmune Reconstitution Inflammatory SyndromeIncidenceMaleMiddle AgedMycobacterium tuberculosisPneumocystis cariniiPneumonia, PneumocystisRNA, ViralTuberculosisUnited StatesViral LoadConceptsImmune reconstitution inflammatory syndromeCD4 cell countCells/μL.HIV RNA levelsHazard ratioTuberculosis incidenceCART initiationCell countAntiretroviral therapyTime-varying CD4 cell countBaseline CD4 cell countAIDS-free individualsEffects of CARTLow tuberculosis incidenceMonths of ARTReconstitution inflammatory syndromeHIV-positive patientsRNA levelsHIV-positive individualsHuman immunodeficiency virusHIV-CAUSAL CollaborationInflammatory syndromeImmunodeficiency virusInverse probability weightingPositive individuals
2011
Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone
Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA, Team F. Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone. Alcohol Clinical And Experimental Research 2011, 36: 318-324. PMID: 21797892, PMCID: PMC3221963, DOI: 10.1111/j.1530-0277.2011.01601.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlanine TransaminaseAlcoholismAntiretroviral Therapy, Highly ActiveAspartate AminotransferasesCD4 Lymphocyte CountChemical and Drug Induced Liver InjuryCohort StudiesDatabases, FactualDrug InteractionsDrug-Related Side Effects and Adverse ReactionsFemaleHIV InfectionsHumansLiverLiver Function TestsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOpioid-Related DisordersRNA, ViralVeteransConceptsNaltrexone prescriptionAlanine aminotransferaseOpioid dependenceVeterans Aging Cohort Study Virtual CohortAspartate aminotransferaseImpact of naltrexoneSignificant alanine aminotransferaseLiver enzyme elevationMean CD4 countHIV-infected individualsAST changesHepatic safetyHIV biomarkersOral naltrexoneCD4 countHIV RNAMedian durationEnzyme elevationMedian ageAST levelsNaltrexone useHepatic enzymesAntiretroviral effectivenessHIVPatientsWhen to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
Cain L, Logan R, Robins J, Sterne J, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher H, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan M. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Annals Of Internal Medicine 2011, 154: 509-15. PMID: 21502648, PMCID: PMC3610527, DOI: 10.7326/0003-4819-154-8-201104190-00001.Peer-Reviewed Original ResearchConceptsCD4 cell countCombined end pointHazard ratioCell countCells/LAntiretroviral therapyCells/L.CD4 cell count thresholdBaseline CD4 cell countEnd pointVeterans Health Administration systemInitiation of cARTThreshold CD4 countCorresponding hazard ratiosMortality hazard ratioAIDS-free survivalProspective observational dataHIV-CAUSAL CollaborationMost clinical guidelinesHealth Administration systemUse of CD4Marginal structural modelsCell count thresholdCART initiationDynamic marginal structural models
2009
Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans.
Crothers K, Goulet JL, Rodriguez-Barradas MC, Gibert CL, Oursler KA, Goetz MB, Crystal S, Leaf DA, Butt AA, Braithwaite RS, Peck R, Justice AC. Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. AIDS Education And Prevention 2009, 21: 40-53. PMID: 19537953, PMCID: PMC3118467, DOI: 10.1521/aeap.2009.21.3_supp.40.Peer-Reviewed Original ResearchConceptsHIV-negative veteransIncidence rate ratiosSmoking statusHIV-negative patientsSimilar mortality riskHIV-positive veteransComorbid diseasesCurrent smokingOverall mortalityCigarette smokingPoor outcomeMortality riskHIVPoisson regressionMortalitySmokingRate ratioVeteransDiseaseStudy of mechanismsLow levelsStatusSmokersPatientsCessation
2008
Impact of Pneumococcal Vaccination on the Incidence of Pneumonia by HIV Infection Status among Patients Enrolled in the Veterans Aging Cohort 5-Site Study
Rodriguez-Barradas MC, Goulet J, Brown S, Goetz MB, Rimland D, Simberkoff MS, Crothers K, Justice AC. Impact of Pneumococcal Vaccination on the Incidence of Pneumonia by HIV Infection Status among Patients Enrolled in the Veterans Aging Cohort 5-Site Study. Clinical Infectious Diseases 2008, 46: 1093-1100. PMID: 18444830, PMCID: PMC3115628, DOI: 10.1086/529201.Peer-Reviewed Original ResearchConceptsPneumococcal polysaccharide vaccineVeterans Aging CohortPPV vaccinationIncidence of pneumoniaAging CohortCox proportional hazards regression methodsLow CD4 cell countsProportional hazards regression methodsCD4 cell countHIV infection statusRisk of pneumoniaLower hemoglobin levelsBenefits of vaccinationHuman immunodeficiency virusOngoing prospective studyElectronic medical recordsPneumococcal vaccinationPneumonia eventsUnvaccinated patientsCurrent smokingPneumococcal diseasePolysaccharide vaccineVaccination statusHIV infectionRetrospective reviewQuantifying the Decrement in Utility from Perceived Side Effects of Combination Antiretroviral Therapies in Patients with HIV
Braithwaite RS, Goulet J, Kudel I, Tsevat J, Justice AC. Quantifying the Decrement in Utility from Perceived Side Effects of Combination Antiretroviral Therapies in Patients with HIV. Value In Health 2008, 11: 975-979. PMID: 18225989, PMCID: PMC3121315, DOI: 10.1111/j.1524-4733.2007.00315.x.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyBothersome symptomsSF-6D utilitiesAntiretroviral therapyCD4 countSide effectsVeterans Aging Cohort StudyAging Cohort StudySF-12 scoresAfrican American raceHazardous alcohol consumptionQuality of lifeRecent drug useCART initiationMild anginaCohort studyMultivariable analysisCigarette smokingUnivariate analysisAmerican raceAlcohol consumptionDrug useUtility decrementsPatientsClinical decision
2007
Do Patterns of Comorbidity Vary by HIV Status, Age, and HIV Severity?
Goulet JL, Fultz SL, Rimland D, Butt A, Gibert C, Rodriguez-Barradas M, Bryant K, Justice AC. Do Patterns of Comorbidity Vary by HIV Status, Age, and HIV Severity? Clinical Infectious Diseases 2007, 45: 1593-1601. PMID: 18190322, PMCID: PMC3687553, DOI: 10.1086/523577.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusCD4 cell countPatterns of comorbidityHIV infectionHIV statusCell countHIV severityOlder human immunodeficiency virusPrimary care guidelinesClinical Modification codesCells/Pulmonary diseaseComorbid conditionsMultivariable analysisViral loadCare guidelinesImmunodeficiency virusComorbiditiesInternational ClassificationMultimorbidityInfectionPresence of conditionsVeteransAgeDisease